Division of Jazz Pharmaceuticals PLC
Latest From Orphan Australia
Australian firms continue to carve a place in their home market – some more successfully than others.
Sigma Pharmaceuticals has reportedly received three offers for its consumer health business Herron Pharmaceuticals and another three for its Orphan Australia drugs division.
The Australian Therapeutics Goods Administration (TGA) has granted orphan status to Orphan Australia's Thromboreductin (anagrelide hydrochloride), 0.5mg and 1mg capsules. Thromboreductin is indicated for the treatment of essential thrombocythaemia in patients with high or intermediate risk of thrombosis or bleeding. It was approved on April 23rd.
Australia's Therapeutics Goods Administration (TGA) designated four new orphan drugs in the end of October.
- Therapeutic Areas
- Parent & Subsidiaries
- Jazz Pharmaceuticals PLC
- Senior Management
- Alastair Young, Managing Dir.
- Contact Info
Phone: (61) 56 298581
1806 Tonimbuk Rd.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.